CSL (OTCMKTS:CSLLY) Hits New 52-Week Low – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares hit a new 52-week low on Thursday . The stock traded as low as $17.00 and last traded at $17.3150, with a volume of 901321 shares changing hands. The stock had previously closed at $17.73.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Zacks Research downgraded shares of CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Royal Bank Of Canada downgraded shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. Finally, Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

CSL Stock Down 2.3%

The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average is $22.33 and its two-hundred day moving average is $43.28.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.